Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.

Pain comes in many forms, and Abbott aims to treat as many as it can with its devices. The company received a new approval from the FDA for its low-dose spinal cord stimulator implant, covering ...

Abbott is putting the old adage that “good things come in threes” to the test, with its fourth FDA approval in less than a year for its spinal cord stimulation (SCS) systems. The latest regulatory nod ...

Abbott's new Proclaim™ Plus spinal cord stimulation (SCS) system offers the next generation of stimulation therapy, giving physicians the ability to treat multi-site and evolving pain The system ...

The U.S. Food and Drug Administration (FDA) approved Abbott (ABT)'s Eterna™ spinal cord stimulation (SCS) system for the treatment of chronic pain This neuromodulation device provides an optimized ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

The FDA approved Abbott Laboratories ABT spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back ...

Abbott Laboratories received U.S. FDA approval for an expanded indication for its spinal cord stimulator (SCS) devices to include treatment of chronic back pain for individuals who have not had or are ...

ABBOTT PARK, Ill., May 16, 2023 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of ...

Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted a ...